65,437 trials
Multiple Myeloma
Primary: Number of Pharmacists Who Had Provided Patients With the Contents of the Risk Management Plan (RMP) Material — 307 Participants
Parkinson Disease · Freezing of Gait
Primary: Recruitment of Sample: Number of Participants Recruited — 12 Participants
Chronic Idiopathic Constipation
Primary: CSBM1 Success Rate — 9; 8 Participants
Crohn's Disease · Ulcerative Colitis
Primary: PROMIS Measures of Pain Interference — 51.2; 51.6; 50.1; 48.2 T-score — p=0.751
Myopia · Myopic Astigmatism
Primary: Percentage of Eyes That Achieve MRSE Predictability Within ±0.50 Diopter (D) and ±1.00 D — 287; 302 Eyes
Chronic Pain
Primary: The Number of Patients Who Agree to Change in Their Opioid Regimen, Including Buprenorphine Transfer — 19 Participants
Bacteremia · Sepsis
Primary: Time to Optimal Antimicrobial Therapy — 31.1; 117.7; 90.0 hours
Plasma Cell Myeloma
Primary: Phase 1: Number of Participants With Dose-Limiting Toxicities (DLTs) — 0 Participants
PTSD · Posttraumatic Stress Disorder
Primary: PTSD Treatment Engagement (Yes/no) — 137; 132 Participants
Refractive Ametropia
Primary: Least Squares Mean Distance VA With Study Lenses at Week 1 — -0.11; -0.10 logMAR
Healthy
Primary: SpO2 Accuracy — 1.24 % of oxygen saturated hemoglobin
Metastatic, Locally Advanced or Unresectable Soft Tissue Sarcoma
Primary: Progression-Free Survival (PFS) — 4.04; 2.96 Months
Cystic Fibrosis
Primary: Absolute Change in Percent Predicted Forced Expiratory Volume in 1second (ppFEV1) — 0.0; 0.2 percentage points — p=< 0.0001
Respiratory Syncytial Virus Infection
Primary: Number of Participants With Immediate Unsolicited Systemic Adverse Events (AEs) — 0; 0; 0; 0 Participants
Spinal Cord Injuries
Primary: Bladder Storage — 278.5; 447.75; 580.5; 313.0 mLH2O